Alzheimer's Drug's Successful Test CTS-21166


	Alzheimer's Drug's Successful Test CTS-21166

BobbyDelray

1-15-2008 12:31 PM

231 views

tags:

alzheimer's, treatment, drug, cts-21166, tang, doctor

Add a Comment

Login to Comment. Not a member yet? Sign up

View the Top Clips from January 15, 2008

Embed This Clip In Your Site...

<div style="margin: 12px 0px; font-family: arial; color: #333333; background: #ffffff; border: solid 4px #e5e5e5; width: 100%; clear: left;"><div class="CM_CTB_Content_Wrap" style="margin: 0px; padding: 0px;background-color: #ffffff;"><div style="border-bottom: solid 1px #dcdcdc; white-space: nowrap; margin-bottom: 8px; background-color: #eeeeee ;background-image: url(http://www.clipmarks.com/images/source-bg.gif); background-repeat: repeat-x; height: 24px; line-height: 24px; vertical-align: middle; padding-bottom: 4px; color: #666666; font-size: 10px;" ><a href="http://clipmarks.com/clip-to-blog/" title="see clips that are hot right now"><img src="http://content.clipmarks.com/blog_embed/50c4cf54-4e87-4195-82c4-d5d6362b4ced/0105A095-9980-4DA7-BDF3-97146A26AAA0/" alt="" width="19" height="19" border="0" style="vertical-align: middle; margin: 0px 4px; display: inline; border: none; float:none;" /></a>clipped from <a title="http://www.omrf.org/OMRF/News_Releases/Releases/2008/20080114.asp" href="http://www.omrf.org/OMRF/News_Releases/Releases/2008/20080114.asp" style="font-size: 11px;">www.omrf.org</a></div><blockquote style="text-align: left; padding: 0px 8px; margin: 4px 0px 8px 0px; background: transparent; border: none;" cite="http://www.omrf.org/OMRF/News_Releases/Releases/2008/20080114.asp">
                        CoMentis, a California/Oklahoma City-based pharmaceutical company, is 
                        developing a beta-secretase inhibitor, CTS-21166, discovered by Dr. Tang and 
                        Dr. Arun Ghosh of Purdue University. Unlike the existing Alzheimer’s drugs 
                        that treat only the symptoms, CTS-21166 inhibits, or turns off, the 
                        mechanism believed to lead to disease progression. The Phase I clinical 
                        trial results showed CTS-21166 to be safe and well tolerated in humans at 
                        various dose levels. Following the administration of a single dose, 
                        CTS-21166 reduced the levels of plasma beta amyloid, a potential cause of 
                        progression of the disease, by as much as 60 percent.</blockquote><div style="height: 2px; font-size: 2px; background: #dcdcdc; border-bottom: solid 1px #f5f5f5; margin: 2px 4px;"></div><blockquote style="text-align: left; padding: 0px 8px; margin: 4px 0px 8px 0px; background: transparent; border: none;" cite="http://www.omrf.org/OMRF/News_Releases/Releases/2008/20080114.asp">
                        “CTS-21166 represents an entirely new approach to the treatment of 
                        Alzheimer’s disease by inhibiting beta-secretase, an enzyme critical in the 
                        production of potentially toxic amyloid beta,” said Henry Hsu, M.D., 
                        CoMentis Chief Medical Officer. “It has the potential to become the 
                        first-in-class disease-modifying therapeutic agent.”</blockquote></div><div style="margin: 0px 6px 6px 4px;"><table style="font-size: 11px;border-spacing: 0px;padding: 0px;" cellpadding="0" cellspacing="0" width="100%"><tr><td style="background:transparent;border-width:0px;padding:0px;">&nbsp;</td><td align="right" style="background:transparent;border-width:0px;padding:0px;width:107px" width="107"><a href="http://clipmarks.com/share/0105A095-9980-4DA7-BDF3-97146A26AAA0/blog/" title="blog or email this clip"><img src="http://content8.clipmarks.com/images/c2b-foot.png" border="0" alt="blog it" width="107" height="17" style="border-width:0px;padding:0px;margin:0px;" /></a></td></tr></table></div></div>